Archive | December, 2014

Panel announcements: Preclinical Investors and Healthcare IT

11 Dec

By Tom Crosby, RESI Conference Manager, LSN

PrecliTom 2nical Investors:

Attracting investors with interest in preclinical technologies has been a strong suit for the RESI Conference in the past, and the event’s premier on the West Coast is no exception. By reaching out to its deep roster of contacts from this investment stage, in which all investor types are now getting involved, LSN has brought together a unique mix of investors for the upcoming Preclinical session.

Moderated by Rajesh Rangantahn, Director of the Office of Translational Research for the NINDS, the audience will hear from:

Michael Recny, CEO, Calvert Holdings

Natalie Dakers, President and CEO,  CDRD

David Berry, Partner, Flagship Ventures

Ron Demuth, President, Torrey Pines Investments

If you’re looking for your first round of investment post-R&D, this diverse group will help you understand the nuances of positioning your company, how to approach the initial correspondence, and which classes of investors are currently interested in what types of technologies. If you’re looking to begin building a strong investor pipeline to get your company off the ground, this session is a good place to start.

Healthcare IT:

Healthcare IT has been a hot topic for investment recently, to say the least. From hospitals and healthcare providers implementing new electronic healthcare systems, to companies creating devices built to track your every move, it is clear that healthcare IT and big data are going to be huge players in life science world going forward.

Moderated by Randy Scott, Partner, HealthQuest Capital, the audience will hear from:

Akhil Saklecha, Partner, Artiman Ventures

Rich Simoni, Partner, Asset Management Ventures

Rik Vandevenne, Director, River Cities Capital Fund

Phillip Sanger, Managing Partner, Texo Ventures

How should healthcare IT companies position themselves to look most attractive in the space? What subsegments of this space are investors currently most interested in? What does the future of healthcare IT have in store? All these questions and more will be answered on January 13th. If you are a fundraising executive working in Healthcare IT, this session will provide you with tactical advice on how best to move forward.




Hot Life Science Investor Mandate 1: US Based Family Office Seeking Global, Seed Stage, Software Enabled Device and HIT Opportunities

11 Dec

A private/family investment vehicle based in the Western United States is seeking to invest in the life science space.  The fund is a structured organization for making angel investments in pre-seed or seed rounds.  Investments are in the form of equity; in the next 6 months the firm expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector.  The firm also provides a three-month accelerator program.  The firm will consider investing in companies worldwide.

The firm is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component.  Healthcare IT, biosensors, wearables and health monitoring devices are of interest.  While the firm is open to investing in any indication, the firm is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders.  In the healthcare IT sector, the firm is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder.  In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 2: Corporate Venture Arm of Global Pharma Company Seeking Early Stage 505(b)(2) Therapeutics

11 Dec

Allocation Information

The corporate venture capital arm of a global pharmaceutical company based in Mumbai, India is actively seeking new investments. The firm has been established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds. The firm has a global mandate and is currently seeking new investment opportunities.

Sectors and Subsectors of Interest

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on oncology, neurology, infectious diseases, and metabolic diseases, but will consider other indications on a case-by-case basis. The firm will prioritize 505(b)(2) opportunities.

Company and Management Team Requirements

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 3: Global PE Firm Looking for Clinical Stage Devices and Therapeutics

11 Dec

A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Partnering Based on Fit!

4 Dec

By Alejandro Zamorano, VP of Business Development, LSN

Alejandro 10*10

LSN announces RESI 4 Partnering Platform has gone live.

The sheer quantity and diversity of investors attending RESI, paired with the power of the RESI Partnering Platform, means the RESI conference is the right place for early stage life science companies to meet investors that are a fit.

LSN has partnered with Meeting Mojo, an emerging partnering portal developer based in the UK. RESI attendees can use the system to find other attendees who are a fit for their product, development stage, and other relevant factors.  This highly customized solution uses metatagged profiles that can be searched by the scientist entrepreneur attendees to pinpoint a specific fit for an investment mandate by one of the investment firms present at RESI. The RESI Partnering Platform provides the foundation for a one-of-a-kind partnering experience based on current investor mandates, easily matchable to the emerging biotech and medtech startups that fit the investment criteria.

RESI partnering therefore provides an opportunity for life science companies and investors to meet the right people, create compelling dialogues, and foster long-term relationships.

Oncology Landscape: Competitive Pipelines and Global Mandates

4 Dec

By Mimi Liu, Research Analyst, LSN 


The global market for cancer drugs and treatments is truly massive and continues to grow. According to the IMS Institute for Healthcare Informatics, global oncology spending hit $91 billion in 2013, and it is growing at a 5% clip annually.[1] In previous articles, we’ve analyzed new products and investor interest in the cardiovascular and neurology sectors. Today, let’s look at what LSN data shows in the oncology sphere.

LSN tracks more than 4,500 therapeutic assets for the neoplasms, cancer, and oncology areas, including 1,025 assets that are in the preclinical stage, 2,202 assets that are in the clinical stage, and 517 assets that are on the market. For some of these therapeutics, LSN is also able to track the type of cancer they target. Although this is a subset of the total, it is useful to analyze. (See Figures 1, 2, and 3.)


Figure 1


Figure 2


Figure 3

Several types of cancer, such as breast, prostate, and pancreatic, are clearly some of the hottest and most competitive areas, representing large patient populations and substantial unmet medical needs. Companies developing therapeutics for these cancers likely find it more challenging to differentiate themselves from competitors than do companies targeting other cancers. It is interesting to note that certain disease areas, such as solid tumors and brain cancer, have attracted significant R&D efforts in the preclinical and clinical stages, yet there are relatively few available products on market. This may reflect a large prospective market but significant R&D challenges.

Companies targeting cancer therapies are spread across the globe. The U.S. has the largest number overall, while the UK, Germany, and France are the European countries with the most. North America and Europe are the two areas with the highest concentration of cancer therapeutics, while several Asian countries, such as China, Japan, and South Korea also have a significant number. (See Figure 4.)


Figure 4

With the growing number of cancer therapies and the expansion of the cancer market, there are a large number of investors with this interest. LSN has interviewed biotech investors across a wide range of categories who are interested in funding companies targeting neoplasm, cancer, and oncology therapeutics. (See Figure 5.)

Venture capital is the largest group among the ten categories of investors. Private equity firms, angel groups, and family offices also show a high interest in cancer companies. When looking for funding, companies should keep an eye on various categories of investors and the development stage they are interested in.


Figure 5

An analysis of investors’ exposure preference by region is strikingly similar to the regional distribution of oncology companies. (See Figure 6.)


Figure 6

Most investors are looking to allocate their capital to U.S.-based companies, which corresponds to the concentration of assets in the country. Although investors are attracted to established markets in North America and Europe, a significant portion will consider emerging markets in Asia and Latin America. Since the oncology investor landscape is rapidly shifting, it is important to note that global investors are the third largest group of investors.

For fundraising entrepreneurs, keeping track of all the different types of investors in an indication like this given the global nature of so many investors today, is no small task. However limiting your research and outreach to only a few classes of investors or just within your local geography will undoubtedly hurt your chances for a successful fundraise. In an indication with as much competition as oncology, investors have to focus on technology and management in order to be successful. More and more they are looking overseas for the best possible opportunities  and as an entrepreneur, you should be doing the same.

[1] “Cancer-drug market zooms toward $100B, thanks to costly targeted therapies,” May 6, 2014,

Double RESI Conference Panel Announcement: Big Pharma & Diagnostic Investors

4 Dec

By Tom Crosby, RESI Conference Manager, LSN

Tom 2This week, LSN announces two panels for the upcoming Redefining Early Stage Investments Conference: Big Pharma & Large Biotech, and Diagnostic Investors.

Panel Announcement #1: Big Pharma

Panelists will discuss in-depth the key motivators behind big pharma’s shift towards an early stage strategy as a way to fill the gaps in their pipelines. What indication areas are currently most sought after? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN’s Big Pharma RESI Panelists will shed light on these questions and more.

Moderated by Tomas Landh, Director, Novo Nordisk, the audience will hear from:

Kevin Lynch, VP, Search and Evaluation, Abbvie

Imran Nasrullah, Director, Innovation Sourcing, Boehringer Ingelheim

Thorsten Melcher, Senior Director, New Ventures & Partnerships, J&J Innovation

Shafique Virani, Global Head, Partnering (Neuro), Roche / Genentech

Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the timeframe and limitations of how big pharma corporate works, this expert session is crucial for you to attend.

Panel Announcement #2: Diagnostic Investors

In addition to drug developers and medical device engineers, LSN also welcomes diagnostic startups to RESI, and for the first time, RESI 4 will present a discussion panel exploring the challenging landscape of the diagnostics sector. The investors joining this panel are highly diverse, representing both nonprofit and for-profit interests in the diagnostics field.

These panelists will discuss what an entrepreneur needs to know about raising capital for an innovative diagnostic product. The panel will explore how to pitch a diagnostic opportunity, how to navigate the strategic challenges in diagnostics, and what will differentiate your product from the pack.

Moderated by Steven Young, President & COO, Addario Lung Cancer Institute, the audience will hear from:

Bill Cadwallader, Senior Commercialization Officer, Diagnostics, PATH

Momei Qu, Senior Associate, Baird Capital

Gary Kurtzman, Senior Vice President and Managing Director, HealthcareSafeguard Scientifics, Inc.

Nola Masterson, Founder and Managing Director, Science Futures

%d bloggers like this: